Shots:
- Prelude Therapeutics entered a clinical trial collaboration and supply agreement with Eli Lilly to evaluate PRT13722, an oral selective KAT6A degrader, in combination with abemaciclib (Verzenio) and imlunestrant (Inluriyo) in pts. with HR+/HER2- breast cancer
- The combination cohorts are part of Prelude’s P-I study, supported by preclinical data demonstrating synergy between PRT13722, CDK4/6 inhibitors, and endocrine therapies across multiple HR+ breast cancer models
- Following US FDA clearance of its IND application, Prelude expects to initiate patient enrollment in Q4’26, beginning with monotx. dose escalation before advancing to various combination cohorts; Prelude retains full global development and commercial rights to PRT13722 as a wholly owned program
Ref: Prelude | Image: Prelude and Eli Lilly | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
